Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip N Newsome

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Gastroenterology|March 29, 2016
Entering the GOLDEN Age for Therapies in NASHPhilip N Newsome
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2013
SOS liver damage; calling all haematopoietic stem cellsPhilip N Newsome
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 8, 2010
Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome?Philip N Newsome
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 29, 2015
Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?Andrew Owen, Philip N Newsome
Digestive Diseases (Basel, Switzerland)|July 19, 2014
Bone marrow stem cell therapy for liver diseaseAndrew King, Philip N Newsome
The Journal of Clinical Investigation|July 1, 2025
Therapeutic horizons in metabolic dysfunction-associated steatohepatitisPhilip N Newsome, Rohit Loomba
The Journal of Clinical Endocrinology and Metabolism|February 19, 2025
NAFLD vs MASLD (metabolic dysfunction associated steatotic liver disease) - why the need for a change of nomenclature?Amalia Gastaldelli, Philip N Newsome
Alimentary Pharmacology & Therapeutics|December 19, 2019
Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyondPaul Horn, Philip N Newsome
Lancet (London, England)|April 23, 2023
Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitisSara Mahgoub, Philip N Newsome
Frontiers in Immunology|July 9, 2020
Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?Andrew Owen, Philip N Newsome
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Gastroenterology|March 29, 2016
Entering the GOLDEN Age for Therapies in NASHPhilip N Newsome
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2013
SOS liver damage; calling all haematopoietic stem cellsPhilip N Newsome
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 8, 2010
Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome?Philip N Newsome
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 29, 2015
Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?Andrew Owen, Philip N Newsome
Digestive Diseases (Basel, Switzerland)|July 19, 2014
Bone marrow stem cell therapy for liver diseaseAndrew King, Philip N Newsome
The Journal of Clinical Investigation|July 1, 2025
Therapeutic horizons in metabolic dysfunction-associated steatohepatitisPhilip N Newsome, Rohit Loomba
The Journal of Clinical Endocrinology and Metabolism|February 19, 2025
NAFLD vs MASLD (metabolic dysfunction associated steatotic liver disease) - why the need for a change of nomenclature?Amalia Gastaldelli, Philip N Newsome
Alimentary Pharmacology & Therapeutics|December 19, 2019
Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyondPaul Horn, Philip N Newsome
Lancet (London, England)|April 23, 2023
Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitisSara Mahgoub, Philip N Newsome
Frontiers in Immunology|July 9, 2020
Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?Andrew Owen, Philip N Newsome
Pageof 20